[{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"3d58d724-7b7a-4521-94a7-0e3dc4880d42","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054374","created_at":"2021-09-23T17:53:02.260Z","updated_at":"2025-02-25T15:35:18.664Z","phase":"Phase 1/2","brief_title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05054374","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124","tags":["HER-2 • ER • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2024-07-09"},{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"9d379a3d-e6e5-4272-912a-3b641b499609","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616183","created_at":"2021-01-19T20:33:33.700Z","updated_at":"2024-07-02T16:35:00.055Z","phase":"Phase 1/2","brief_title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04616183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • MAP2K1","pipe":"","alterations":" ","tags":["KRAS • BRAF • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"92b543b8-0666-45b8-8525-786af02d2693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418167","created_at":"2021-01-18T21:17:40.725Z","updated_at":"2024-07-02T16:35:20.996Z","phase":"Phase 1","brief_title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","source_id_and_acronym":"NCT04418167","lead_sponsor":"JS InnoPharm, LLC","biomarkers":" MAP2K1 • NF1 • RASA1","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["MAP2K1 • NF1 • RASA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • JSI-1187"],"overall_status":"Suspended","enrollment":" Enrollment 71","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/17/2024","study_completion_date":" 12/17/2024","last_update_posted":"2024-02-02"},{"id":"31f0020c-0510-41ca-b50a-168b2e6ddd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03087071","created_at":"2021-01-18T15:12:32.712Z","updated_at":"2024-07-02T16:35:25.486Z","phase":"Phase 2","brief_title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","source_id_and_acronym":"NCT03087071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • MAP2K1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type","tags":["KRAS • BRAF • NRAS • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-12-21"},{"id":"ee56db09-450a-4a94-add8-8f5116440e80","acronym":"","url":"https://clinicaltrials.gov/study/NCT02881242","created_at":"2021-01-18T14:08:42.806Z","updated_at":"2025-02-25T15:53:28.853Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02881242","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" EGFR • MAP2K1","pipe":"","alterations":" ","tags":["EGFR • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-05-01"},{"id":"ec19f33b-7b3a-4da5-8e6a-47575a751dbe","acronym":"HEM-iSMART D","url":"https://clinicaltrials.gov/study/NCT05658640","created_at":"2022-12-21T15:59:05.726Z","updated_at":"2024-07-02T16:35:58.797Z","phase":"Phase 1/2","brief_title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05658640 - HEM-iSMART D","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" FLT3 • NRAS • HRAS • MAP2K1 • NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation","tags":["FLT3 • NRAS • HRAS • MAP2K1 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2022-12-21"},{"id":"69112ba3-2ae8-4897-864e-b49a99d79bf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771404","created_at":"2021-01-18T18:39:31.761Z","updated_at":"2024-07-02T16:37:04.768Z","phase":"","brief_title":"NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"","source_id_and_acronym":"NCT03771404","lead_sponsor":"Hellenic Oncology Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-11"}]